期刊文献+

腹膜透析血液高凝状态与心血管事件的关系 被引量:2

The Relationship of Hypercoagulability of Blood in Peritoneal Dialysis and Cardiovascular Events
下载PDF
导出
摘要 腹膜透析患者存在血液高凝状态,且较血液透析及慢性肾衰竭保守治疗更为严重,其原因与内皮细胞、血小板等诸多因素相关。心血管并发症为腹膜透析患者最主要的死因,而血液高凝状态是腹透患者发生心血管事件的重要病因,明确血液高凝状态形成的原因及机制,掌握预防血液高凝状态的形成的方法,对于控制腹透患者心血管并发症具有极为重要的意义。 High coagulation state of blood exists in peritoneal dialysis patients, which is even more severe than patients treated by hemodialysis and conservative treatment, and the reason is related to endothelial activation,increased platelet count and other factors. Cardiovascular complication is the leading cause of death among peritoneal dialysis patients, while the high coagulation state of blood can lead to cardiovascular disease, therefore clarifying the cause and mechanisms of the high coagulation state of blood has great significance for controlling cardiovascular complications in peritoneal dialysis patients.
出处 《医学综述》 2015年第10期1754-1756,共3页 Medical Recapitulate
关键词 腹膜透析 血液高凝 心血管事件 Peritoneal dialysis High coagulation state of blood Cardiovascular event
  • 相关文献

参考文献26

  • 1房艳辉,蒋兰萍,周紫娟,王海云,徐红,李雪梅,陈丽萌,李学旺.腹膜透析患者脂质代谢紊乱与腹膜转运功能及生存的关系[J].中国医学科学院学报,2013,35(3):327-331. 被引量:7
  • 2Neves M,Machado S,Rodrigues L,et al.Cardiovascular risk in peritoneal dialysis-a Portuguese multicenter study[J].Nefrologia,2014,34(2):205-211.
  • 3Trappenburg MC,van Schilfgaarde M,Frerichs FC,et al.Chronic renal failure is accompanied by endothelial activation and a large increase in microparticle numbers with reduced procoagulant capacity[J].Nephrol Dial Transplant,2012,27(4):1446-1453.
  • 4Caballo C,Palomo M,Cases A,et al.NFκB in the development of endothelial activation and damage in uremia:an in vitro approach[J].PLo S One,2012,7(8):e43374.
  • 5Koc-Zorawska E,Malyszko J,Zbroch E,et al.VAP-1 in peritoneally dialyzed patients[J].Postepy Hig Med Dosw(Online),2013,67:1340-1344.
  • 6Dong J,Li YJ,Yang ZK,et al.Prognosyic vallie of serlm von willebrand factor,but not sollble icam and vcam,for mortality and cardiovasclilar events is independent of residlial renal function inperitoneal dialysis patients[J].Perit Dial In,2014,34(7):706-713.
  • 7Han SH,Lee SC,Kang EW,et al.Reduced residual renal function is associated with endothelial dysfunction in patients receiving peritoneal dialysis[J].Perit Dial Int,2012,32(2):149-158.
  • 8Kovaˇcevi P,Dragi S,Rajkovaˇca Z,et al.Serum levels of nitric oxide and endothelin-1 in patients treated with continuous ambulatory peritoneal dialysis[J].Ren Fail,2014,36(3):437-440.
  • 9Enia G,Panuccio V,Mallamaci F,et al.Fibrinogen and calcium x phosphate product are predictors of cardiovascular events in the CAPD population[J].J Nephrol,2005,18(6):764-769.
  • 10Hryszko T,Malyszko J,Malyszko JS,et al.Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor[J].Thromb Res,2001,104(4):233-238.

二级参考文献14

  • 1Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis [J]. N Engl J Med, 2009, 360(14) :1395-1407.
  • 2Cho KH, Kim H J, Kamanna VS, et al. Niacin improves re- nal lipid metabolism and slows progression in chronic kidney disease [J ]. Biochim Biophys Acta, 2010, 1800 (1 : 6-15.
  • 3Baroni G, Schuinski A, de Moraes TP, et al. Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis [ J ]. Mediat Inflam- mation, 2012(2012) :912595.
  • 4Yung S, Chan TM. Pathophysiology of the peritoneal mem- brane during peritoneal dialysis: the role of hyaluronan [ J ]. J Biomed Biotechnol, 2011 (2011 ) : 180594.
  • 5Stavenuiter AW, Schilte MN, Ter Wee PM, et al. Angiogenesis in peritoneal dialysis [J]. Kidney Blood Press Res, 2011, 34(4) :245-252.
  • 6Samouilidou EC, Karpouza AP, Kostopeulos V, et al. Lipid abnormalities and oxidized LDL in chronic kidney disease pa- tients on hemodialysis and peritoneal dialysis [ J]. Ren Fail, 2012, 34(2') :160-164.
  • 7Mou S, Wang Q, Fang W, et al. Change in cardiovascular disease status in peritoneal dialysis patients: a 5-year single- center experience [ J]. Ren Fail, 2012, 34(1) :28-34.
  • 8Fytili CI, Progia EG, Panagoutsos SA, et al. Lipoprotein ab- normalities in hemodialysis and continuous ambulatory perito- neal dialysis patients [ J ]. Ren Fail, 2002, 24 ( 5 ) : 623-630.
  • 9Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and in- cidence of cancer during 10-year follow-up of the Scandinavi- an Simvastatin Surv!val Study (4S) [J]. Lancet, 2004, 364 (9436) :771-777.
  • 10Wanner C, Krane V, Mm'z W, et aL Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [J]. N Engl J Med, 2005, 353(3) :238-248.

共引文献6

同被引文献13

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部